Strategy
CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.
Amgen’s AI model to predict proteins in the “bright Goldilocks zone of viscosity” with over 80% accuracy minus a wet lab experiment holds immense potential, VP Research Haldar said at an event as he spoke about a “hinge moment” for AI in pharma
The Biovelocita II fund is supported by the likes of Amgen, Bristol Myers Squibb and Pfizer
Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.
The company sees potential for the GLP-1/glucagon receptor dual agonist in MASH as well as alcohol-related liver disease as hopes to move pemvidutide into Phase III in obesity with a partner.
Plus deals involving Hyundai/Pharma/Avelos, Yuhan/Boehringer Ingelheim, SciClone/Eisai, Viatris/Nxera/Idorsia, Nxera/Holling and Takeda/BridGene.
A joint venture with AI specialist Hologen will bring in much-needed cash for the ambitious gene therapy firm.
A stake acquisition in US venture Illexcor allows India's Zydus to get in on the ground floor for a potential once-daily sickle cell disease treatment. The candidate showed promising preclinical results in a field that has yielded mixed outcomes for global majors like Novartis, Pfizer and Novo Nordisk
Both vexed by bankruptcies and opioid litigation, Endo and Mallinckrodt will merge in a deal valued at $6.7bn. The new company will spin out its generics and sterile injectable business.
CEO Adam Steensberg has led a major change in fortunes for the Danish biotech since March 2022.
Ono agreed to pay $280m up front for global rights to Ionis’s Phase II polycythemia vera candidate, which analysts say was de-risked by recent data reported for other PV drugs.
Scrip senior writer Joseph Haas discusses recent industry merger-and-acquisition activity with attorneys Jessica Bisignano and Gabrielle Witt of Hogan Lovells.
The Swiss giant has inked a deal potentially worth $5.30bn with Zealand to access the Danish biotech's long-acting amylin analog petrelintide.
Zydus Lifesciences plans to expand global markets for patented products of French orthopedic tech company Amplitude Surgicals which it is acquiring from PE firm PAI Partners and others. Could the European business also serve as a buffer to upheaval in the US amid talks of tariffs?
A Phase III trial testing the protein degrader in breast cancer met the primary endpoint and showed an efficacy benefit only in the subgroup of ESR1 mutant patients, not the full population.
Chairman Antoine Papiernik spoke to Scrip about the therapeutic areas that where the VC major is looking at to invest its considerable cash pile.
Can India’s Mittelstand or small and medium enterprises win the quality game and what could help? Sectoral insights from defense and FMCG industries and from other countries like Germany might hold the key for Indian pharma, a panel of experts at a recent event opined.
Battling AstraZeneca in the aldosterone inhibitor space, Mineralys reports Phase III data showing lorundrostat can significantly decrease uncontrolled/resistant blood pressure at six weeks.
A Phase IIa trial studying Haduvio for the treatment of refractory chronic cough showed a benefit for patients, opening the door to a broad market and impressing investors.
Having bested BMS's oral psoriasis drug Sotyktu, the closely watched once-daily IL-23 blocker is going head-to-head with J&J's own autoimmune mega-blockbuster Stelara.